Takeda Pharmaceutical (NYSE:TAK) Insider Andrew Stewart Plump Sells 165,393 Shares

Takeda Pharmaceutical Co. (NYSE:TAK) insider Andrew Stewart Plump sold 165,393 shares of the firm’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $17.10, for a total value of $2,828,220.30. Following the sale, the insider owned 766,569 shares of the company’s stock, valued at $13,108,329.90. The trade was a 17.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Takeda Pharmaceutical Trading Down 0.3%

NYSE:TAK opened at $17.42 on Thursday. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.14 and a quick ratio of 0.62. Takeda Pharmaceutical Co. has a fifty-two week low of $12.99 and a fifty-two week high of $18.90. The stock’s 50-day moving average is $16.49 and its two-hundred day moving average is $17.13. The stock has a market cap of $55.82 billion, a PE ratio of 51.24 and a beta of -0.08.

Takeda Pharmaceutical (NYSE:TAK) last posted its quarterly earnings results on Tuesday, March 31st. The company reported $0.56 earnings per share (EPS) for the quarter. The business had revenue of $6.90 billion during the quarter. Takeda Pharmaceutical had a net margin of 3.80% and a return on equity of 10.95%. As a group, equities research analysts forecast that Takeda Pharmaceutical Co. will post 3.01 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. Weiss Ratings lowered shares of Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday, July 30th. Zacks Research raised shares of Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 4th. Finally, Wall Street Zen upgraded Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a report on Saturday, July 18th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold”.

Hedge Funds Weigh In On Takeda Pharmaceutical

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Private Trust Co. NA grew its position in Takeda Pharmaceutical by 84.7% in the fourth quarter. Private Trust Co. NA now owns 1,707 shares of the company’s stock worth $27,000 after acquiring an additional 783 shares in the last quarter. Parkside Financial Bank & Trust raised its holdings in shares of Takeda Pharmaceutical by 192.2% during the 4th quarter. Parkside Financial Bank & Trust now owns 2,560 shares of the company’s stock valued at $40,000 after purchasing an additional 1,684 shares in the last quarter. SHP Wealth Management bought a new position in shares of Takeda Pharmaceutical during the 4th quarter valued at $42,000. Caitong International Asset Management Co. Ltd lifted its stake in shares of Takeda Pharmaceutical by 313.7% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,070 shares of the company’s stock valued at $48,000 after purchasing an additional 2,328 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. lifted its stake in shares of Takeda Pharmaceutical by 56.3% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 3,586 shares of the company’s stock valued at $55,000 after purchasing an additional 1,292 shares during the last quarter. Institutional investors own 9.17% of the company’s stock.

More Takeda Pharmaceutical News

Here are the key news stories impacting Takeda Pharmaceutical this week:

• Neutral Sentiment: The sales were explicitly made to cover tax-withholding obligations tied to the vesting of equity awards, rather than representing discretionary open-market selling. Each insider retained a substantial stake after the transactions, reducing the concern that management is broadly abandoning the company. SEC insider filing
• Negative Sentiment: The volume and seniority of the sellers could weigh on investor sentiment. CEO Julie So-Young Kim sold 89,090 shares, while Andrew Stewart Plump sold 165,393 shares. General Counsel Natalie Anne Marie Furney, Giles Richard Platford, Lauren Rusckowski Duprey and several other insiders also reduced their holdings, with individual ownership declines ranging from about 6.6% to 18.5%. SEC insider filing

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.